Coinbase CEO Brian Armstrong plans to fund a startup focused on gene editing in human embryos, a first for the private sector in a field long shaped by
the CRISPR controversy. He is recruiting scientists to apply base editing, a DNA-altering method considered more precise than earlier tools, to target genetic disease. The effort may test legal and ethical limits in the US.